Skip to content

Re-link HCV in Substance-Use Telemedicine Program

Hepatitis C

This is an observational, retrospective \& prospective cohort study. The retrospective element of the study is a chart review to identify people with diagnosed but untreated HCV and re-link them to care. The observational prospective cohort element of the study will examine the HCV linkage to care, treatment initiation, treatment completion \& cure rates of these HCV clients achieved through this chart review and re-linking approach.

null

Conditions de participation

  • Sexe:

    ALL

  • Âges admissibles:

    0 and up

Critères de participation

Inclusion Criteria:

For the retrospective chart review element of the study, inclusion criteria includes anyone who had a telemedicine visit at the community based substance use telemedicine program between January 1st 2023 and December 31st 2024.

For the prospective cohort element of the study, the inclusion criteria are listed below:

Aged ≥18. Ability and willingness of the participant to provide informed consent. Having a positive HCV RNA laboratory result and lacking a sufficient previous course of DAA treatment.

Exclusion Criteria:

For the retrospective chart review element of the study, exclusion criteria is: a consent directive to restrict access to their OLIS record.

For the prospective cohort study, exclusion criteria is an inability or unwillingness of the participant to provide informed consent.

-

Lieu de l'étude

trueNorth Medical Centre
trueNorth Medical Centre
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Hannah O'Reilly, BSc

[email protected]
8888783563
Étude parrainée par
trueNorth Medical Centres
Participants recherchés
Plus d'informations
ID de l'étude: NCT06349902